These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9636823)

  • 1. Cost-effectiveness of interferon-alpha for chronic myeloid leukemia.
    Goldman JM
    Ann Oncol; 1998 Apr; 9(4):351-2. PubMed ID: 9636823
    [No Abstract]   [Full Text] [Related]  

  • 2. The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review.
    Garside R; Round A; Dalziel K; Stein K; Royle P
    Health Technol Assess; 2002; 6(33):1-162. PubMed ID: 12633529
    [No Abstract]   [Full Text] [Related]  

  • 3. Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?
    Goldman J
    Nat Clin Pract Oncol; 2005 Mar; 2(3):126-7. PubMed ID: 16264901
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-effectiveness of interferon in chronic myeloid leukaemia: analysis of four clinical studies.
    Messori A
    Ann Oncol; 1998 Apr; 9(4):389-96. PubMed ID: 9636829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of interferon-alpha as maintenance therapy in chronic myelogenous leukemia.
    Messori A; Becagli P; Trippoli S
    Ann Intern Med; 1997 Apr; 126(8):664-5. PubMed ID: 9103145
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of interferon alfa in chronic myelogenous leukemia.
    Liberato NL; Quaglini S; Barosi G
    J Clin Oncol; 1997 Jul; 15(7):2673-82. PubMed ID: 9215840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia.
    Dalziel K; Round A; Garside R; Stein K
    Pharmacoeconomics; 2005; 23(5):515-26. PubMed ID: 15896102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug treatment of chronic myeloid leukemia: a cost effectiveness analysis of first- and second-line treatment ].
    Groot MT; Ossenkoppele GJ; Kramer MH; van den Boom G; Huijgens PC; Uyl-de Groot CA
    Ned Tijdschr Geneeskd; 2003 Jul; 147(30):1460-5. PubMed ID: 12908349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Reed SD; Anstrom KJ; Ludmer JA; Glendenning GA; Schulman KA
    Cancer; 2004 Dec; 101(11):2574-83. PubMed ID: 15493042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic Evaluations of Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia in Middle- and High-Income Countries: A Systematic Review.
    Fu J; Liu Y; Lin H; Wu B
    Clin Drug Investig; 2018 Dec; 38(12):1167-1178. PubMed ID: 30232698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Position paper on imatinib mesylate in chronic myeloid leukaemia.
    O'Brien SG; Rule SA
    Br J Haematol; 2002 Oct; 119(1):268-72. PubMed ID: 12358935
    [No Abstract]   [Full Text] [Related]  

  • 12. Interferon-alpha and cytosine arabinoside therapy in chronic myeloid leukemia.
    Ezaki K
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():279-84. PubMed ID: 10895166
    [No Abstract]   [Full Text] [Related]  

  • 13. Alpha-interferon in the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.
    Tura S; Baccarani M
    Blood; 1995 May; 85(10):2999-3002. PubMed ID: 7742563
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effectiveness of treatment with native alpha-interferon (Wellferon) in patients with chronic myeloid leukemia].
    Rukavitsyn OA
    Vopr Onkol; 1997; 43(6):606-9. PubMed ID: 9479361
    [No Abstract]   [Full Text] [Related]  

  • 15. [The effectiveness of interferon-alpha therapy in Ph-positive chronic myeloid leukemia].
    Bogdanov KV; Frolova OI; Marinets OV; Ogorodnikova IuS; Afanas'ev BV; Zaritskiĭ AIu
    Vopr Onkol; 2003; 49(2):189-92. PubMed ID: 12785203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predominantly BCR-ABL negative myeloid precursors in interferon-alpha treated chronic myelogenous leukemia: a follow-up study of peripheral blood colony-forming cells with fluorescence in situ hybridization.
    Sick C; Schultheis B; Pasternak G; Kottke I; Hörner S; Heissig B; Hehlmann R
    Ann Hematol; 2001 Jan; 80(1):9-16. PubMed ID: 11233781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The M.D. Anderson Cancer Center experience with interferon-alpha therapy in chronic myelogenous leukaemia.
    Talpaz M; Kantarjian HM; O'Brien S; Kurzrock R
    Baillieres Clin Haematol; 1997 Jun; 10(2):291-305. PubMed ID: 9376665
    [No Abstract]   [Full Text] [Related]  

  • 18. Is there still a role for interferon-alpha for newly diagnosed chronic myeloid leukemia in chronic phase?
    Quintás-Cardama A; Verstovsek S
    Leuk Lymphoma; 2007 Mar; 48(3):445-6. PubMed ID: 17454579
    [No Abstract]   [Full Text] [Related]  

  • 19. The effectiveness of interferon-α combined with imatinib in patient with chronic myeloid leukemia harboring T315I BCR-ABL1 mutation.
    Zhang H; Liang Z; Hu Y; Wang X; Wang B; Huang H
    Leuk Lymphoma; 2018 Dec; 59(12):3018-3019. PubMed ID: 29616854
    [No Abstract]   [Full Text] [Related]  

  • 20. Imatinib mesylate--a new oral targeted therapy.
    Savage DG; Antman KH
    N Engl J Med; 2002 Feb; 346(9):683-93. PubMed ID: 11870247
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.